MADRID (Reuters) – It is too early to say whether combining Roche’s best-selling Avastin cancer drug with the company’s experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors.
That is the verdict of experts following a presentation of a…
Gain from adding Roche’s Avastin to immune drug unclear
No comments:
Post a Comment